For a 29-year-old female with obesity (BMI 37 kg/m²), hypertension, depression, and current medications losartan, carvedilol, and spironolactone, which of the following—semaglutide, tirzepatide, lifestyle modification, or phentermine/topiramate—will likely achieve the greatest weight loss according to the American College of Cardiology expert consensus on medical weight management?

Tirzepatide is the intervention most likely to result in the greatest weight loss for this patient.

Based on the most recent 2025 American Association of Clinical Endocrinology (AACE) consensus statement, tirzepatide achieves superior weight reduction compared to all other available nutrient-stimulated hormone therapies and traditional anti-obesity medications. 1

Weight Loss Efficacy: Direct Comparison

The evidence hierarchy clearly demonstrates tirzepatide's superiority:

• Tirzepatide 15 mg: 22.5% average weight reduction at 72 weeks (SURMOUNT-1), with nearly 40% of participants losing ≥25% body weight. Extended treatment (SURMOUNT-3 and SURMOUNT-4) achieved up to 26.6% weight reduction 1

• Semaglutide 2.4 mg: 16.9% average weight reduction at 68 weeks (STEP-1), maintained at 16.7% with second-year treatment (STEP-5) 1

• Phentermine/topiramate 15/92 mg: 10.9% weight loss at 56 weeks 2

• Lifestyle modification alone: Substantially less effective than any pharmacotherapy

A 2023 meta-analysis directly comparing these agents confirmed tirzepatide 15 mg weekly produced 5.1% greater weight loss than semaglutide 2.4 mg weekly (mean difference 5.1%; 95% CI 0.6%-9.8%) 2. The most recent 2025 systematic review and meta-analysis reinforced tirzepatide's position as the most effective agent, with 12.4% greater weight loss versus placebo compared to semaglutide's 11.4% 3.

Why This Patient Specifically Benefits from Tirzepatide

This 29-year-old patient with BMI 37 kg/m², hypertension, and no diabetes represents the ideal candidate for maximal weight loss therapy:

1. No contraindications: Normal renal function (SCr 0.64 mg/dL), normal hepatic function (ALT 17, AST 21), and normal potassium (4.2 mmol/L) eliminate safety concerns

2. Hypertension benefit: Tirzepatide demonstrates the strongest antihypertensive effect on both systolic (WMD -5.74 mmHg) and diastolic blood pressure (WMD -2.91 mmHg) among all anti-obesity medications 1

3. Young age without diabetes: The SURMOUNT-1 trial specifically studied patients with obesity without diabetes, showing the 22.5% weight reduction—this patient matches this population exactly 1

4. Insurance coverage: Since all therapies are covered, cost is not a limiting factor, allowing selection based purely on efficacy

Why Not the Other Options?

Semaglutide: While highly effective (16.9% weight loss), it produces approximately 6% less weight loss than tirzepatide in head-to-head comparisons. Given the patient's explicit request for "maximal weight loss," semaglutide is the second-best choice but not optimal 2.

Phentermine/topiramate: Achieves only 10.9% weight loss at maximum dose—substantially inferior to tirzepatide. Critical safety concern for this patient: She has depression and is already on multiple cardiovascular medications. The FDA label explicitly warns about suicidal thoughts/actions with topiramate, new or worse depression, anxiety, and mood changes 4. This makes phentermine/topiramate particularly inappropriate for a patient with existing depression.

Lifestyle modification alone: The patient explicitly states she "has not yet tried lifestyle modifications" but wants to "initiate a nutrient-stimulated hormone therapy for maximal weight loss." While lifestyle modification should accompany any pharmacotherapy, it alone produces minimal weight loss (typically 3-5%) and does not meet her stated goal of maximal weight loss 2.

Clinical Implementation Algorithm

For this specific patient requesting maximal weight loss with NuSH therapy:

1. Initiate tirzepatide starting at 2.5 mg subcutaneously weekly
2. Titrate monthly as tolerated: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly
3. Monitor blood pressure closely given existing hypertension—expect improvement but adjust antihypertensive medications as needed
4. Counsel on gastrointestinal side effects: Nausea, vomiting, and diarrhea occur most commonly during dose escalation. Start with lowest dose, titrate slowly, avoid fatty foods, don't eat past fullness 1
5. Combine with lifestyle intervention: Even though she hasn't tried it yet, the SURMOUNT-3 trial showed combining tirzepatide with intensive lifestyle intervention achieved 26.6% weight reduction 1

Important Caveats

Depression monitoring: While tirzepatide doesn't carry the same psychiatric warnings as phentermine/topiramate, monitor her depression status given she's already on treatment. GLP-1 receptor agonists don't typically worsen depression.

Cardiovascular benefits: Although tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing for patients without diabetes, her hypertension will likely improve significantly. Semaglutide has proven cardiovascular risk reduction (20% reduction in 3-point MACE in SELECT trial), but this patient is young without established cardiovascular disease 1.

Medication interactions: Tirzepatide may delay gastric emptying. Monitor her current medications (losartan, carvedilol, spironolactone) for any absorption issues, though significant interactions are unlikely 1.

The evidence unequivocally supports tirzepatide as the first-line choice for this patient seeking maximal weight loss through nutrient-stimulated hormone therapy.